Indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA). Vabitiv® should be used only in situations where it is known or suspected that other alternatives are not suitable.
Rapid Review
Commenced | Completed | Outcome |
08/12/2014 | 13/01/2015 | Full Pharmacoeconomic Evaluation Not Recommended |